ATE416251T1 - Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren - Google Patents
Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimierenInfo
- Publication number
- ATE416251T1 ATE416251T1 AT01946696T AT01946696T ATE416251T1 AT E416251 T1 ATE416251 T1 AT E416251T1 AT 01946696 T AT01946696 T AT 01946696T AT 01946696 T AT01946696 T AT 01946696T AT E416251 T1 ATE416251 T1 AT E416251T1
- Authority
- AT
- Austria
- Prior art keywords
- gene
- rsv
- genes
- genome
- shifted
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 16
- 241000700605 Viruses Species 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 230000001681 protective effect Effects 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 8
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 abstract 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 abstract 1
- 102100024407 Jouberin Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 abstract 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 230000008707 rearrangement Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18541—Use of virus, viral particle or viral elements as a vector
- C12N2760/18543—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21370800P | 2000-06-23 | 2000-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE416251T1 true ATE416251T1 (de) | 2008-12-15 |
Family
ID=22796187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01946696T ATE416251T1 (de) | 2000-06-23 | 2001-06-22 | Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1294858B1 (enExample) |
| JP (1) | JP2004515218A (enExample) |
| KR (1) | KR100899030B1 (enExample) |
| CN (1) | CN1468301A (enExample) |
| AT (1) | ATE416251T1 (enExample) |
| AU (3) | AU6870901A (enExample) |
| BR (1) | BRPI0112276B8 (enExample) |
| CA (1) | CA2413786A1 (enExample) |
| DE (1) | DE60136811D1 (enExample) |
| ES (1) | ES2317914T3 (enExample) |
| IL (1) | IL153530A0 (enExample) |
| MX (1) | MXPA02012818A (enExample) |
| WO (1) | WO2002000693A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003530073A (ja) * | 1999-07-09 | 2003-10-14 | アメリカ合衆国 | 弱毒化されたヒト−ウシキメラ呼吸器合胞体ウィルスワクチンの製造 |
| WO2008094200A2 (en) * | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc | Chimeric virus-like particles |
| WO2008094197A2 (en) | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| WO2011056899A2 (en) | 2009-11-03 | 2011-05-12 | Ligocyte Pharmaceuticals, Inc. | Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps |
| CN105200069A (zh) * | 2015-10-16 | 2015-12-30 | 北京交通大学 | 基于rna聚合酶ⅰ的rsv微型复制基因组及其应用 |
| CA3007474A1 (en) * | 2015-12-11 | 2017-06-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant respiratory syncytial virus strains comprising ns1 and ns2 gene shifts |
| CN110229219B (zh) * | 2019-06-21 | 2021-03-30 | 中国科学院武汉病毒研究所 | 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2112220A3 (en) * | 1996-07-15 | 2010-01-06 | The Government of the United States of America, as represented by The Department of Health and Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
-
2001
- 2001-06-22 EP EP01946696A patent/EP1294858B1/en not_active Expired - Lifetime
- 2001-06-22 BR BR0112276-2 patent/BRPI0112276B8/pt not_active IP Right Cessation
- 2001-06-22 AU AU6870901A patent/AU6870901A/xx active Pending
- 2001-06-22 KR KR1020027017577A patent/KR100899030B1/ko not_active Expired - Fee Related
- 2001-06-22 JP JP2002505815A patent/JP2004515218A/ja active Pending
- 2001-06-22 IL IL15353001A patent/IL153530A0/xx not_active IP Right Cessation
- 2001-06-22 AU AU2001268709A patent/AU2001268709B2/en not_active Ceased
- 2001-06-22 DE DE60136811T patent/DE60136811D1/de not_active Expired - Lifetime
- 2001-06-22 CA CA002413786A patent/CA2413786A1/en not_active Abandoned
- 2001-06-22 WO PCT/US2001/020107 patent/WO2002000693A2/en not_active Ceased
- 2001-06-22 MX MXPA02012818A patent/MXPA02012818A/es active IP Right Grant
- 2001-06-22 ES ES01946696T patent/ES2317914T3/es not_active Expired - Lifetime
- 2001-06-22 CN CNA018143628A patent/CN1468301A/zh active Pending
- 2001-06-22 AT AT01946696T patent/ATE416251T1/de not_active IP Right Cessation
-
2006
- 2006-12-22 AU AU2006252238A patent/AU2006252238A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0112276B1 (pt) | 2019-12-31 |
| ES2317914T3 (es) | 2009-05-01 |
| CA2413786A1 (en) | 2002-01-03 |
| CN1468301A (zh) | 2004-01-14 |
| IL153530A0 (en) | 2003-07-06 |
| DE60136811D1 (de) | 2009-01-15 |
| EP1294858B1 (en) | 2008-12-03 |
| KR100899030B1 (ko) | 2009-05-21 |
| AU6870901A (en) | 2002-01-08 |
| KR20030045685A (ko) | 2003-06-11 |
| WO2002000693A3 (en) | 2002-09-26 |
| BRPI0112276B8 (pt) | 2021-05-25 |
| MXPA02012818A (es) | 2003-05-14 |
| WO2002000693A2 (en) | 2002-01-03 |
| AU2006252238A1 (en) | 2007-01-25 |
| EP1294858A2 (en) | 2003-03-26 |
| JP2004515218A (ja) | 2004-05-27 |
| AU2001268709B2 (en) | 2006-09-28 |
| BR0112276A (pt) | 2004-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE419369T1 (de) | Chimäre mensch-rinder respiratory syncytial virus vakzinen | |
| Lu et al. | A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike | |
| WO2001042445A3 (en) | USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS | |
| NO20025171L (no) | DNA-transfeksjonssystem for fremstilling av smittsom influensavirus | |
| MXPA01013302A (es) | Vacunas para el virus de la parainfluenza (piv) quimerico para humanos-bovinos atenuadas. | |
| PL1951296T5 (pl) | Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego poprzez traktowanie beta-propiolaktonem | |
| MY202396A (en) | Hbv vaccine | |
| PH12020500526A1 (en) | Paramyxoviridae expression system | |
| Cibulski et al. | A novel Anelloviridae species detected in Tadarida brasiliensis bats: first sequence of a chiropteran Anellovirus | |
| WO2010079505A3 (en) | Combined measles-human papilloma vaccine | |
| ATE416251T1 (de) | Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren | |
| CY1107786T1 (el) | Συστηματα εκφρασεως και εμβολια ανασυνδυασμενου ιου rsv | |
| WO2008048984A3 (en) | Methods and compositions for preparing a universal influenza vaccine | |
| BRPI0504945B8 (pt) | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. | |
| WO2011038473A8 (pt) | Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos | |
| Nagata et al. | Efficacy of DNA vaccination against western equine encephalitis virus infection | |
| Bartlett et al. | Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys | |
| ZA202101156B (en) | New attenuated virus strain and use thereof as a vaccine | |
| DK177298B1 (en) | Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines | |
| WO2002002605A3 (en) | Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines | |
| Zhang et al. | Immunogenicity of a recombinant Sendai virus expressing the capsid precursor polypeptide of foot-and-mouth disease virus | |
| Matveev | Psychological aspects of history e-learning | |
| Sizova | ECOLOGY OF SARS-CoV-2 AND INFLUENZA COINFECTION | |
| TH62970A (th) | วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum) | |
| PL397433A1 (pl) | Sposób wytwarzania szczepionki rekombinowanej przy uzyciu technologii DNA immunologicznego produktu leczniczego weterynaryjnego dla golebi domowych |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |